NAARDEN, The Netherlands, and MUNICH, October 1, 2018-- Forbion, a leading European life science venture capital firm, has today announced the final close of its new flagship fund, Forbion IV. The oversubscribed fund closed at EUR 360 million in capital commitments, significantly above its original target of EUR 250 million. Forbion IV, like its predecessor fund, Forbion III, will primarily focus on opportunities in the EU including the UK, with the remainder of the fund targeting opportunities mainly in North America.